IVERIC bio Revenue and Competitors
Estimated Revenue & Valuation
- IVERIC bio's estimated annual revenue is currently $19.1M per year.
- IVERIC bio's estimated revenue per employee is $67,130
- IVERIC bio's total funding is $382.9M.
- IVERIC bio's current valuation is $1.6B. (January 2022)
Employee Data
- IVERIC bio has 284 Employees.
- IVERIC bio grew their employee count by 52% last year.
IVERIC bio Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.1M | 7 | 250% | N/A | N/A |
#2 | $5.9M | 38 | 15% | N/A | N/A |
#3 | $34.7M | 224 | 6% | N/A | N/A |
#4 | $5.2M | 67 | 0% | $10M | N/A |
#5 | $2M | 13 | 0% | N/A | N/A |
#6 | $7.5M | 37 | 0% | $51.6M | N/A |
#7 | $0.9M | 6 | -14% | N/A | N/A |
#8 | $4.3M | 21 | -16% | $3.3M | N/A |
#9 | $4.2M | 27 | -16% | N/A | N/A |
#10 | $4.3M | 56 | -8% | $118M | N/A |
What Is IVERIC bio?
IVERIC bio is a gene therapy focused company developing innovative treatments for patients with orphan inherited retinal diseases with significant unmet medical needs. We have a diversified and scientifically compelling pipeline of product candidates. At IVERIC bio we understand the critical importance of vision in the quality of life of patients.
keywords:N/A$382.9M
Total Funding
284
Number of Employees
$19.1M
Revenue (est)
52%
Employee Growth %
$1.6B
Valuation
N/A
Accelerator
IVERIC bio News
IVERIC bio, Inc. (NASDAQ:ISEE Get Rating) has received a consensus recommendation of Buy from the eight research firms that are...
IVERIC bio also reported earnings of ($0.29) per share during the same quarter last year. The business is scheduled to issue its next earnings...
IVERIC bio Inc is a biopharmaceutical company focused on the discovery and development of novel treatment options for retinal diseases with...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $39.7M | 284 | 4% | $100.9M |
#2 | $64M | 284 | 8% | N/A |
#3 | $56.2M | 284 | N/A | N/A |
#4 | $64M | 284 | 0% | N/A |
#5 | $50M | 284 | 25% | N/A |